Craigavon, N.I., 07 Aug 2019 – Almac Group, the global contract pharmaceutical development and manufacturing organization, is privileged to be included in the top ten list of “Ulster Business Top 100 companies” for the second consecutive year.
The news comes as the Group’s figures for year ending 30 September 2018 reported a £17 million rise in revenue at £548 million with pre-tax profits recorded at £27 million.
In a supplementary table listing the most valuable firms in Northern Ireland, the global organization, now with a tangible net worth of £285.7 million, was recorded in eighth position while it was listed as the second highest employer which had increased in 2017/18 by over 8% to 4,798.
Kevin Stephens, Almac Group Finance Director, commented: “As we celebrate 50 years of success I am delighted to see Almac highly ranked in the Ulster Business Top 100 companies once again. We are committed to providing our growing client base with the most innovative and efficient service in our marketplace and achieving recognition in this listing, published by Ulster Business, is testament to the continued dedication and contribution of our ever increasing global and diverse employee base.”
The Ulster Business Top 100 list is sponsored by A&L Goodbody and uses a combination of data sourced from both Dun & Bradstreet’s information database and Companies House. It incorporates the results of Northern Ireland based companies, either Northern Ireland registered, or when a significant portion of their business is driven and transacted through the province.
Michael Neill, head of office, A&L Goodbody Belfast, said: “The results of this resilience and determination speak for themselves in this year’s Top 100 rankings, with collective turnover increasing by 9.4% in the 12 months to £24.8bn. While many companies are long-standing players and remain unchallenged at the top end of the rankings, it is positive to see businesses continue to rise up the ranks, year-on-year.”
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately-owned organization that has organically grown over 50 years and now employs over 5,000 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 operations across Europe, the US (Pennsylvania, North Carolina and California) and Asia (Singapore and Tokyo).